Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ClinOleic + Omegaven is an intravenous lipid emulsion combination used primarily in parenteral nutrition for the prevention and treatment of parenteral nutrition-associated cholestasis (PNAC) and intestinal failure-associated liver disease (IFALD), especially in neonates and pediatric patients. The mixture typically combines olive oil/soybean oil-based lipids (ClinOleic) with fish oil-based lipids rich in omega-3 fatty acids (Omegaven), often at a 1:1 or 2:1 ratio. This combination provides essential fatty acids while reducing the risk of liver complications associated with traditional soybean oil-based emulsions. Mechanistically, it supplies energy, essential fatty acids, and modulates inflammatory responses by altering the balance of omega-6 to omega-3 polyunsaturated fatty acids. Clinical studies have shown improved outcomes in infants with short bowel syndrome or IFALD when using this combination compared to standard lipid emulsions[2][3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ClinOleic + Omegaven.